Huppa and colleagues highlight signaling deficiencies in chimeric antigen receptor (CAR)-modified T cells that limit the efficacy of CAR T cell therapies to target tumors with diminished antigen expression.
- Venugopal Gudipati
- Julian Rydzek
- Johannes B. Huppa
